Laboratory Investigation

Kidney International (1991) 40, 453–460; doi:10.1038/ki.1991.232

A glomerular permeability factor produced by human T cell hybridomas

Akio Koyama1, Masami Fujisaki1, Masaki Kobayashi1, Masaya Igarashi1 and Mitsuharu Narita1

1Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan

Correspondence: Dr A Koyama, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, 305 Japan.

Received 29 October 1990; Revised 30 April 1991; Accepted 1 May 1991.

Top

Abstract

A glomerular permeability factor produced by human T cell hybridomas. T cell hybridomas derived from the T cells of a patient with minimal change nephrotic syndrome (MCNS) made a glomerular permeability factor (GPF). Sufficient quantities of GPF were available for further analysis and characterization. We obtained four stable clones of human T cell hybridomas which produced a glomerular permeability factor. When this factor was injected intravenously into rats, significant proteinurias were induced, and in normal human lymphocyte culture, GPF enhanced Concanavalin-A (Con-A) induced lymphocyte histogenesis by greater than ten fold. GPF was cytotoxic to tumor cell lines of epithelial origin, but only cytostatic to tumor cells of hematopoietic origin. Electron microscopy studies, with polyethyleneimine (PEI) staining, indicated that GPF induced the changes in the arrangement of PEI particles and partial fusion of glomerular epithelial cells in the rats given this factor intravenously. The molecular weight of GPF were estimated to be between 60,000 and 160,000 daltons. The molecular weight of the factor and its TNF like activity, we speculated that the factor was a lymphokine, like lymphotoxins.

Top

References

  1. Cameron JS: Histology, proteinuria and response to treatment in the nephrotic syndrome. Br Med J iv:352–356, 1968
  2. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T cell function. Lancet ii:566–559, 1974
  3. Lagrue G, Xhemermont S, Branellec A, Hirbec G, Weil B: A vascular permeability factor elaborated from lymphocytes. 1. Demonstration in patients with nephrotic syndrome. Biomedicine 23:37–40, 1975 | PubMed | ISI | ChemPort |
  4. Sobel AT, Branellec AI, Blanc CJ, Lagrue GA: Physico-chemical characterization of a vascular permeability factor produced by Con A-stimulated human lymphocytes. J Immunol 119:1230–1234, 1977 | PubMed | ISI | ChemPort |
  5. Sasdelli M, Rovinetti C, Cagnoli L, Beltrandi E, Barboni F, Zueehelli P: Lymphocyte subpopulations in minimal-change nephropathy. Nephron 25:72–76, 1980 | PubMed | ISI | ChemPort |
  6. Soothil JF: Is steroid-responsive nephrotic syndrome an immunopathogenic disease? Pediatrician 10:343–350, 1981
  7. Foder P, Saitu MT, Rodriquez E, Gonzalez B, Schlesinger L: T-cell dysfunction in minimal change nephrotic syndrome of childhood. Am J Dis Child 136:713–717, 1982
  8. Matsumoto K, Osakabe K, Katayama H, Okano K, Watanabe S, Hatano M: Impaired delayed hypersensitivity in lipoid nephrosis. Nephron 37:273–275, 1984
  9. Moorthy AV, Zimmerman SW, Burkholder PM: Inhibition of lymphocyte blastogenesis by plasma of patients with minimal change nephrotic syndrome. Lancet i:1160–1162, 1976
  10. Minchin MA, Turner KJ, Bower GD: Lymphocyte blastogenesis in nephrotic syndrome. Clin Exp Immunol 42:241–246, 1980
  11. Sasdelli M, Rovinetti C, Cagnoli L, Beltrandi E, Barboni F, Zucchelli P: Lymphocyte subpopulations in minimal change nephropathy. Nephron 25:72–76, 1980 | PubMed | ISI | ChemPort |
  12. Taube D, Brown Z, Williams DG: Impaired lymphocyte and suppressor cell function in minimal-change nephropathy, membranous nephropathy and focal glomerulosclerosis. Clin Nephrol 22:176–182, 1984 | PubMed |
  13. Tomizawa S, Maruyama K, Nagasawa N, Suzuki S, Kuroume T: Studies on vascular permeability factor derived from T-lymphocytes and inhibitory effect of plasma on its production in minimal change nephrotic syndrome. Nephron 41:157–160, 1985 | PubMed | ISI | ChemPort |
  14. Heyer JR, Raij L, Vernier RL, Simmons RL, Najarian JS, Michael AF: Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet ii:343, 1972
  15. Yoshizawa N, Kusumi Y, Matsumoto K, Oshima S, Takeuchi A, Kawamura O, Kubota T, Kondo S, Niwa H: Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 51:370–376, 1989 | PubMed | ISI | ChemPort |
  16. Fishman JA, Karnovsky MJ: Effects of the aminonucleoside of puromycin on glomerular epithelial cells in vitro. Am J Pathol 118:398–407, 1985 | PubMed | ISI | ChemPort |
  17. Goldsby RA, Osborne BA, Simpson E, Herzenberg LA: Hybrid cell lines with T cell characteristics. Nature 267:707–708, 1977 | Article | PubMed | ISI | ChemPort |
  18. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of protein from polyarcylamide gels to nitrocellulose sheets; Procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354, 1979 | Article | PubMed | ChemPort |
  19. Takasugi M, Klein E: A microassay for cell-mediated immunity. Transplantation 9:219–227, 1970 | PubMed | ChemPort |
  20. Baranes JL, Radnik RA, Gilchrist EP, Venkatachalam MA: Size and charge selective permeability defects induced in glomerular basement membrane by a polycation. Kidney Int 25:11–19, 1984
  21. Carrie BJ, Salyer WR, Myers BD: Minimal change nephropathy; An electrochemical disorder of the glomerular membrane. Am J Med 70:262–268, 1981 | Article | PubMed | ISI | ChemPort |
  22. Pilla PA, Swain RP, Williams AV, Loadholt CB, Ainsworth SK: Glomerular anionic site distribution in nonproteinuric rats. A computer-associated morphometric analysis. Am J Pathol 121:474–485, 1985
  23. Boulton-Jones JM, Tulloch I, Dore B, Mclay A: Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 20:72–77, 1983 | PubMed | ChemPort |
  24. Churg J, Sobin LH: Renal Disease. Igaku-shoin, Tokyo, New York, 1982, p. 226
  25. Henkart PA: Mechanism of lymphocyte mediated cytotoxity. Ann Rev Immunol 3:31–58, 1985
  26. Shinkai Y, Takio K, Okumura K: Homology of perforin to the ninth complement of comporment (C9). Nature 334:525–527, 1988 | Article | PubMed | ChemPort |
  27. Thomson N, Kraft N: Normal human serum also contains the lymphotoxin found in minimal change nephropathy. Kidney Int 31:1186–1193, 1987 | PubMed | ISI | ChemPort |
  28. Paul NL, Ruddle NH: Lymphotoxin. Ann Rev Immunol 6:407–438, 1988 | Article | ISI | ChemPort |
  29. Gray PW: Cloning and expression of a cDNA for human lymphotoxin a lymphokine with human necrosis activity. Nature 312:721–724, 1984 | Article | PubMed | ISI | ChemPort |
  30. Wang AM, Creasey AA, Ladner MB, Lin AS, Strickler J, Van Arsdell N, Yamamoto R, Mark DF: Molecular cloning of the complementary DNA human tissue necrosis factor. Science 228:149–154, 1985 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT